-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 18, Beijing Wu and Boao Pharmaceuticals declared five new drugs, Sangzhi total alkaloid tablets approved by the State Drug Administration for the treatment of type 2 diabetes.
is the first new drug approved for diabetes in nearly 10 years.
mulberry total alkaloid is a water-soluble alkaloid derived from natural mulberry, a new glycoside enzyme inhibitor, which can inhibit the degradation of oligosaccharides and dissaccharides in food by competing with the reversible competition of glycoside enzymes in the small intestine brush, reducing blood sugar rise and fluctuation.
long-term use can not only significantly reduce the blood sugar on an empty stomach and after meals, but also effectively control the "glycation of hemoglobin" to reduce or delay the occurrence and development of complications.
Sangzhi total alkaloid tablets II, PHASE III clinical led by Beijing Concord Hospital, more than 30 Chinese and Western medicine clinical institutions to participate in the internationally recognized "chemical drugs" as a control, "glycifyed hemoglobin" as the clinical evaluation of the efficacy indicators of modern Chinese medicine. The results of the
showed that the efficacy of the drug was accurate, there was a good dose effect relationship, it would not cause hypoglycemia, and was less absorbed into blood, and the risk of liver and kidney toxicity in long-term drug use was lower.
V and Boao official website shows that, compared with traditional Chinese medicine, the total alkaloid of Sangzhi has broken through the defects of unclear, uncontrollable quality, inaccurate efficacy and no quantitative relationship of crude medicine, and compared with chemical drugs, it makes up for the short board of safety hazards of long-term drug use of single-targeted drugs.
approval of the drug, will change the oral anti-sugar drug market has been dominated by chemical drugs, although a wide variety of traditional Chinese medicine but a very small market share of the embarrassing situation.
.
